No Data
No Data
Express News | Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025
Express News | Rapport Therapeutics Inc - Rap-219 Well Tolerated in Mad-2 Trial
Express News | Rapport Therapeutics Announces New Phase 1 Data, Further Supporting Rap-219's Transformative Potential for CNS Disorders
SIG Maintains Canadian National Railway(CNI.US) With Hold Rating, Cuts Target Price to $115
Canadian National Railway Co. Stock Falls Wednesday, Underperforms Market
Canadian Natl Railway Price Target Cut to $115.00/Share From $125.00 by Susquehanna
No Data